Michel Pairet

Chief Executive Officer at

Boehringer Ingelheim Corporate Center GmbH

67 year

27 connections

Health Technology

Finance

Commercial Services

Profile

Michel Pairet currently works at Boehringer Ingelheim RCV GmbH & Co. KG, as Director, Boehringer Ingelheim Corporate Center GmbH, as Co-Managing Director, C.H.
Boehringer Sohn AG & Co. KG, as Member -Management Board, and Boehringer Ingelheim International GmbH, as Member-Management Board.
Dr. Pairet also formerly worked at Eyevensys SAS, as Director, Okairos AG, as Director, and Boehringer Ingelheim (Venture Capital), as Head from 2014 to 2016.

Michel Pairet active positions

Companies	Position	Start
Boehringer Ingelheim RCV GmbH & Co. KG Boehringer Ingelheim RCV GmbH & Co. KG BiotechnologyHealth Technology Develops and supplies biotherapeutic proteins, plasmid DNA and antibody fragments	Director/Board Member	-
Boehringer Ingelheim International GmbH Boehringer Ingelheim International GmbH Pharmaceuticals: MajorHealth Technology Engages in development, manufacturing and marketing of medicines for humans & animals	Corporate Officer/Principal	31/12/1996
C.H. Boehringer Sohn AG & Co. KG C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immuno-oncology therapies and veterinary drugs	Corporate Officer/Principal	-
Boehringer Ingelheim Corporate Center GmbH Boehringer Ingelheim Corporate Center GmbH Real Estate DevelopmentFinance Leases real estate properties	Chief Executive Officer	-

All active positions of Michel Pairet

Former positions of Michel Pairet

Companies	Position	End
Boehringer Ingelheim (Venture Capital) Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm focuses on companies operating in groundbreaking innovation including cancer, auto-immunity indications, digital solutions, infectious disease and regenerative medicine services. It provides financing for seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes board seat.	President	31/12/2015
Okairos AG Okairos AG Pharmaceuticals: MajorHealth Technology Discovers and develops preventive and therapeutic vaccines against human chronic infectious diseases	Director/Board Member	-
Eyevensys SAS Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Develops non-viral gene therapy process for the treatment of ocular illnesses	Director/Board Member	-

See the detail of Michel Pairet's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michel Pairet's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	7
C.H. Boehringer Sohn AG & Co. KG C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immuno-oncology therapies and veterinary drugs	Health Technology
Okairos AG Okairos AG Pharmaceuticals: MajorHealth Technology Discovers and develops preventive and therapeutic vaccines against human chronic infectious diseases	Health Technology
Boehringer Ingelheim RCV GmbH & Co. KG Boehringer Ingelheim RCV GmbH & Co. KG BiotechnologyHealth Technology Develops and supplies biotherapeutic proteins, plasmid DNA and antibody fragments	Health Technology
Boehringer Ingelheim International GmbH Boehringer Ingelheim International GmbH Pharmaceuticals: MajorHealth Technology Engages in development, manufacturing and marketing of medicines for humans & animals	Health Technology
Boehringer Ingelheim (Venture Capital) Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm focuses on companies operating in groundbreaking innovation including cancer, auto-immunity indications, digital solutions, infectious disease and regenerative medicine services. It provides financing for seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes board seat.	Finance
Eyevensys SAS Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Develops non-viral gene therapy process for the treatment of ocular illnesses	Commercial Services
Boehringer Ingelheim Corporate Center GmbH Boehringer Ingelheim Corporate Center GmbH Real Estate DevelopmentFinance Leases real estate properties	Finance